# 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02509546** · PHASE1,PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** 8-Chloroadenosine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02509546
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-02
- **Primary completion:** 2021-03-09
- **Final completion:** 2021-03-16
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509546, "8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02509546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*